 |
|
The First International Consensus on Mucous Membrane Pemphigoid
Definition, Diagnostic Criteria, Pathogenic Factors, Medical Treatment, and Prognostic Indicators
Lawrence S. Chan, MD;
A. Razzaque Ahmed, MD;
Grant J. Anhalt, MD;
Wolfgang Bernauer, MD;
Kevin D. Cooper, MD;
Mark J. Elder, MD;
Jo-David Fine, MD;
C. Stephen Foster, MD;
Reza Ghohestani, MD, PhD;
Takashi Hashimoto, MD;
Thanh Hoang-Xuan, MD;
Gudula Kirtschig, MD;
Neil J. Korman, MD, PhD;
Susan Lightman, PhD;
Francina Lozada-Nur, DDS, MPH;
M. Peter Marinkovich, MD;
Bartly J. Mondino, MD;
Catherine Prost-Squarcioni, MD, PhD;
Roy S. Rogers III, MD;
Jane F. Setterfield, MD;
Dennis P. West, PhD;
Fenella Wojnarowska, MD;
David T. Woodley, MD;
Kim B. Yancey, MD;
Detlef Zillikens, MD;
John J. Zone, MD
Arch Dermatol. 2002;138:370-379.
Objective We aimed to develop consensus-based recommendations for streamlining
medical communication among various health care professionals, to improve
accuracy of diagnosis and treatment, and to facilitate future investigations
for mucous membrane pemphigoid.
Participants Because of the highly specific nature of this group of diseases, the
26 invited participants included either international scholars in the field
of mucous membrane pemphigoid or experts in cutaneous pharmacology representing
the 3 medical disciplines ophthalmology, oral medicine, and dermatology.
Evidence The first author (L.S.C.) conducted a literature search. Based on the
information obtained, international experts who had contributed to the literature
in the clinical care, diagnosis, and laboratory investigation for mucous membrane
pemphigoid were invited to participate in a consensus meeting aimed at developing
a consensus statement.
Consensus Process A consensus meeting was convened and conducted on May 10, 1999, in Chicago,
Ill, to discuss the relevant issues. The first author drafted the statement
based on the consensus developed at the meeting and the participants' written
comments. The draft was submitted to all participants for 3 separate rounds
of review, and disagreements were reconciled based on literature evidence.
The third and final statement incorporated all relevant evidence obtained
in the literature search and the consensus developed by the participants.
The final statement was approved and endorsed by all 26 participants.
Conclusions Specific consensus-based recommendations were made regarding the definition,
diagnostic criteria, pathogenic factors, medical treatment, and prognostic
indicators for mucous membrane pemphigoid. A system of standard reporting
for these patients was proposed to facilitate a uniform data collection.
From the Department of Dermatology, Northwestern University Medical
School, Chicago, Ill (Drs Chan and West); Department of Oral Medicine and
Diagnostic Sciences, Harvard School of Dental Medicine, Boston, Mass (Dr Ahmed);
Department of Dermatology, Johns Hopkins Medical Institute, Baltimore, Md
(Dr Anhalt); Department of Ophthalmology, University of Zurich, Zurich, Switzerland
(Dr Bernauer); Department of Dermatology, Case Western Reserve University
School of Medicine, Cleveland, Ohio (Drs Cooper and Korman); Department of
Ophthalmology, Christchurch Hospital, Christchurch, New Zealand (Dr Elder);
Department of Dermatology, University of North Carolina, Chapel Hill (Dr Fine);
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard
Medical School, Boston (Dr Foster); Department of Dermatology, Thomas Jefferson
Medical College, Philadelphia, Pa (Dr Ghohestani); Department of Dermatology,
Kurume University School of Medicine, Fukuoka, Japan (Dr Hashimoto); Department
of Ophthalmology, Hôpital Bichat, Paris, France (Dr Hoang-Xuan); Department
of Dermatology, Urije University, Amsterdam, the Netherlands (Dr Kirtschig);
Moorfields Eye Hospital and Institute of Ophthalmology, University College
London, London, England (Dr Lightman); Department of Stomatology, School of
Dentistry, University of California, San Francisco (Dr Lozada-Nur); Department
of Dermatology, Stanford University School of Medicine, Stanford, Calif, and
Veterans Affairs Health Care System, Palo Alto, Calif (Dr Marinkovich); Jules
Stein Eye Institute and Department of Ophthalmology, University of California,
Los Angeles (Dr Mondino); Department of Dermatology and Policliniqe de Dermatologie,
Hôpital Saint-Louis, Paris, France (Dr Prost-Squarcioni); Department
of Dermatology, Mayo Clinic, Rochester, Minn (Dr Rogers); St John's Institute
of Dermatology, St Thomas' Hospital, London, England (Dr Setterfield); Department
of Dermatology, Churchill Hospital, Oxford, England (Dr Wojnarowska); Division
of Dermatology, University of Southern California, Los Angeles (Dr Woodley);
Dermatology Branch, Division of Clinical Sciences, National Cancer Institute,
National Institutes of Health, Bethesda, Md (Dr Yancey); Department of Dermatology,
University of Wurzburg, Wurzburg, Germany (Dr Zillikens); and Department of
Dermatology, University of Utah, Salt Lake City (Dr Zone).
RELATED ARTICLE
Interventions for Mucous Membrane Pemphigoid/Cicatricial Pemphigoid and Epidermolysis Bullosa Acquisita: A Systematic Literature Review
Gudula Kirtschig, Dédée Murrell, Fenella Wojnarowska, and Nonhlanhla Khumalo
Arch Dermatol. 2002;138(3):380-384.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients.
Canizares et al.
Arch Dermatol 2006;142:1457-1461.
ABSTRACT
| FULL TEXT
Successful treatment of mucous membrane pemphigoid with infliximab.
Heffernan and Bentley
Arch Dermatol 2006;142:1268-1270.
FULL TEXT
Identification of an Epitope within Human Integrin {alpha}6 Subunit for the Binding of Autoantibody and Its Role in Basement Membrane Separation in Oral Pemphigoid
Rashid et al.
J. Immunol. 2006;176:1968-1977.
ABSTRACT
| FULL TEXT
Mucous Membrane Pemphigoid of the Vulva
Goldstein et al.
Obstet Gynecol 2005;105:1188-1190.
ABSTRACT
| FULL TEXT
Vesiculo-erosive Oral Mucosal Disease--Management with Topical Corticosteroids: (1) Fundamental Principles and Specific Agents Available
Gonzalez-Moles and Scully
J. Dent. Res. 2005;84:294-301.
ABSTRACT
| FULL TEXT
Vesiculo-erosive Oral Mucosal Disease--Management with Topical Corticosteroids: (2) Protocols, Monitoring of Effects and Adverse Reactions, and the Future
Gonzalez-Moles and Scully
J. Dent. Res. 2005;84:302-308.
ABSTRACT
| FULL TEXT
A Practical Technique for Differentiation of Subepidermal Bullous Diseases: Localization of In Vivo-Bound IgG by Laser Scanning Confocal Microscopy
Wozniak et al.
Arch Dermatol 2003;139:1007-1011.
ABSTRACT
| FULL TEXT
Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune Mucocutaneous Blistering Diseases
Ahmed and Dahl
Arch Dermatol 2003;139:1051-1059.
ABSTRACT
| FULL TEXT
How Can We Diagnose and Treat Mucous Membrane Pemphigoid?
Journal Watch Dermatology 2002;2002:6-6.
FULL TEXT
Interventions for Mucous Membrane Pemphigoid/Cicatricial Pemphigoid and Epidermolysis Bullosa Acquisita: A Systematic Literature Review
Kirtschig et al.
Arch Dermatol 2002;138:380-384.
ABSTRACT
| FULL TEXT
|
